Bluejay Diagnostics, INC 8-K filings

Bluejay Diagnostics reported Q2 2026 results, highlighting the completion of SYMON-II study enrollment and a strengthened balance sheet with approximately $9.6 million in cash, supporting advancement of its Symphony IL-6 test toward regulatory submission and commercialization.

Bluejay Diagnostics announced the successful completion of patient enrollment in its SYMON-II clinical validation study, enrolling 750 patients ahead of schedule.

Bluejay Diagnostics stockholders approved a stock plan amendment and authorized a potential reverse stock split.

Bluejay Diagnostics has completed a private placement of common stock and warrants, raising $8.5 million in gross proceeds to fund FDA approval efforts and operations.

Bluejay Diagnostics has entered into a strategic manufacturing agreement with Argonaut Manufacturing Services to establish scalable U.S.-based production for its Symphony platform.

Bluejay Diagnostics reports Q1 2026 progress on its Symphony IL-6 test, with strong enrollment in its pivotal SYMON-II study and advancements in manufacturing readiness.

Bluejay Diagnostics announced the successful enrollment of 624 patients in its SYMON-II pivotal clinical trial for the Symphony platform, nearing its target of 750 patients.

Bluejay Diagnostics, Inc. completed a private placement of 62,500 common shares to its officers and directors, raising $125,000 at $2.00 per share.

Bluejay Diagnostics acknowledged NorthStrive Fund II LP's proposal for a therapeutic program acquisition, affirming its focus on the Symphony platform while committing to evaluate the new opportunity.

Bluejay Diagnostics announced its Symphony IL-6 Test abstract was accepted for presentation at the 2026 Society of Academic Emergency Medicine Annual Meeting, detailing new clinical data from the SYMON-I study.

Bluejay Diagnostics provided a corporate update, highlighting progress on its Symphony platform for sepsis risk assessment and outlining strategic priorities for 2026, alongside financial results for 2025.

Bluejay Diagnostics announced that all prefunded warrants from its October 2025 private placement have been fully exercised, resulting in approximately 972,000 common shares outstanding.

Bluejay Diagnostics announced the successful completion of commercial-scale production for IL-6 antibodies, crucial for its Symphony System.

Bluejay Diagnostics reports progress in its SYMON-II clinical trial, secures recent financing, and outlines future capital needs for FDA submission of its Symphony IL-6 test.

Bluejay Diagnostics, a medical diagnostics company, closed a $4.5 million private placement to fund FDA approval efforts, R&D, and working capital.

Bluejay Diagnostics, Inc. has expanded its strategic partnership with Sanyoseiko Co., Ltd. to accelerate the commercialization of its Symphony near-patient testing platform.

Bluejay Diagnostics announces new Board and committee chair appointments as part of a routine governance review.

Bluejay Diagnostics announced Q2 2025 financial results and provided updates on its pivotal SYMON-II clinical trial, manufacturing, and financing efforts.

Bluejay Diagnostics, Inc. has amended its license and supply agreements with Toray Industries, Inc., extending a critical manufacturing site establishment deadline but incurring new financial and operational obligations.

Bluejay Diagnostics, Inc. announced the results of its 2025 annual meeting, where stockholders re-elected all directors and approved proposals for potential reverse stock splits.

Bluejay Diagnostics, Inc. provided a mid-year update detailing progress in its SYMON clinical program, significant financial losses, aggressive cost-saving measures including headcount reduction, and plans for a substantial capital raise and potential reverse stock split to maintain Nasdaq listing.

Bluejay Diagnostics, Inc. announced the formal separation of employment with its Chief Technology Officer, Jason Cook, effective May 30, 2025, under a mutually agreed separation agreement.

Bluejay Diagnostics secures approximately $3.7 million in gross proceeds through a warrant inducement transaction with existing warrant holders.

Bluejay Diagnostics has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a deficiency previously disclosed in March.

Bluejay Diagnostics has enacted a 1-for-50 reverse stock split to reduce its outstanding shares and maintain its Nasdaq listing.

Bluejay Diagnostics' stockholders have approved a proposal to authorize a reverse stock split, with the final decision on implementation and ratio left to the Board of Directors.

Bluejay Diagnostics has amended its bylaws to lower the quorum requirement for stockholder meetings from a majority to one-third of voting shares.

Bluejay Diagnostics has increased its authorized shares to 250 million and is working to regain compliance with Nasdaq's minimum bid price requirement.

Bluejay Diagnostics' stockholders voted to approve an increase in authorized shares and the issuance of Class C and Class D warrants at a special meeting on August 21, 2024.

Bluejay Diagnostics has successfully priced an $8.75 million public offering, including common stock or pre-funded warrants, along with Class C and Class D warrants.